Product image of Mycofenolaat Mofetil Sandoz (Mycophenolate Mofetil) supplied by GNH India

Mycofenolaat Mofetil Sandoz

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycofenolaat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaat Mofetil Sandoz, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH India supplies Mycofenolaat Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Manufacturer / TM Owner

Sandoz B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is employed in several immunologically mediated conditions, primarily to inhibit lymphocyte proliferation and reduce graft rejection.

  • Kidney transplant rejection: helps maintain graft function by suppressing immune response.
  • Heart transplant rejection: reduces the risk of acute and chronic rejection episodes.
  • Liver transplant rejection: supports long‑term graft survival through immunosuppression.
  • Lupus nephritis: mitigates renal inflammation and proteinuria in patients with systemic lupus erythematosus.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanosine nucleotide synthesis, a critical pathway for lymphocyte proliferation, thereby suppressing T‑ and B‑cell activation and attenuating immune‑mediated graft rejection or autoimmune inflammation.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools that may affect hydration.
  • Headache: transient cranial discomfort.
  • Abdominal pain: cramping or discomfort in the stomach area.
  • Tremor: mild shaking of hands or limbs.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Opportunistic infections: increased susceptibility to viral, bacterial, or fungal pathogens.
  • Severe leukopenia: marked reduction in white blood cells.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease.
  • Malignancy: heightened risk of certain cancers with long‑term use.
  • Severe anemia: significant drop in red blood cell count.

Precautions & Warnings

Patients receiving Mycofenolaat Mofetil should be monitored closely for safety and efficacy.

  • Monitor blood counts: regular CBC to detect leukopenia or anemia.
  • Assess renal function: periodic serum creatinine and eGFR measurements.
  • Avoid use in pregnancy: drug is classified as Category D due to fetal risk.
  • Screen for infections: evaluate for latent viral infections before initiation.
  • Adjust dose in hepatic impairment: consider reduced exposure in liver disease.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Mycophenolate Mofetil may interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression.
  • Live vaccines: increased risk of vaccine‑derived infection.
  • Cholesterol‑binding resins (e.g., cholestyramine): may reduce drug absorption.
  • Ribavirin: heightened hematologic toxicity.
  • High‑dose acyclovir: potential for renal toxicity.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., azole antifungals): may increase mycophenolate levels.
  • NSAIDs: can exacerbate renal impairment.
  • ACE inhibitors or ARBs: monitor for additive effects on kidney function.
  • Warfarin: possible alteration of anticoagulant effect.
  • Diuretics: watch for electrolyte disturbances.

Frequently Asked Questions

Mycofenolaat Mofetil Sandoz contains mycophenolate mofetil, an immunosuppressant used to prevent rejection of kidney, heart, and liver transplants and to treat lupus nephritis by reducing abnormal immune activity.

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks guanosine nucleotide synthesis, limiting the proliferation of T and B lymphocytes and thereby suppressing the immune response.

The prescribed dose of Mycofenolaat Mofetil is individualized by the treating physician based on the specific transplant protocol or lupus nephritis regimen, patient weight, renal function, and concomitant therapies.

Mycofenolaat Mofetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—IMPDH inhibition—resulting in less nephrotoxicity but a higher incidence of gastrointestinal side effects and bone‑marrow suppression. Choice of therapy depends on the transplant protocol and patient tolerance.

Store Mycofenolaat Mofetil at temperatures below 25 °C in its original container, protecting it from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Mycofenolaat Mofetil is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once or twice daily—must be prescribed by a qualified healthcare professional.

Serious risks include opportunistic infections, severe leukopenia or anemia, hepatic dysfunction, and rare but potentially fatal conditions such as progressive multifocal leukoencephalopathy (PML) and certain malignancies. Regular monitoring of blood counts and liver function is essential.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation, those who are pregnant, or individuals with uncontrolled infections should avoid using Mycofenolaat Mofetil. Clinicians should also exercise caution in patients with severe hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT